Figure 3From: A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder CGI-I at final on-therapy visit (LOCF), ITT population. Back to article page